🇺🇸 FDA
Patent

US 11602551

Use of inosine for the treatment of t-reg deficiency

granted A61KA61K31/708A61K35/747

Quick answer

US patent 11602551 (Use of inosine for the treatment of t-reg deficiency) held by The Board of Regents of the University of Texas System expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/708, A61K35/747, A61P, A61P37/00